Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hilton Hotels Corporation Common Stock (HLT) vs Merck & Co., Inc. (MRK) Price & Performance

Hilton Hotels Corporation Common StockTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Hilton Hotels Corporation Common Stock vs Merck & Co., Inc. — how do they compare? Hilton Hotels Corporation Common Stock trades at $321.21 (market cap $70.82B), while Merck & Co., Inc. trades at $131.58 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 4.5× Hilton Hotels Corporation Common Stock's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

HLTMRK
Market Cap
$70.82B$321.77B
Sector
Consumer CyclicalHealth
52-Week High
$350.22$131.84
52-Week Low
$256.75$77.60
Enterprise Value
$83.83B$368.53B
Dividend Yield
0.19%2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hilton Hotels Corporation Common Stock

Hilton Worldwide Holdings (HLT) trades at $311.00, down 2.08% over 24 hours, amid a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS of $2.29 meeting estimates and revenue growth to $12.04 billion in 2025. However, a high P/E of 46.21 and rising debt-to-asset ratio to 73.88% in 2025 highlight valuation and leverage concerns. Recent news includes a 50-day strike at a Seattle hotel and mixed institutional trading activity.

The outlook for HLT is cautiously optimistic, supported by robust travel demand and a record pipeline, but tempered by premium valuation and debt risks. Analysts maintain a buy consensus with a $352.00 price target, suggesting 13% upside. Key risks include labor disputes, soft international demand, and interest rate sensitivity. Investors should weigh growth prospects against financial leverage and market sentiment shifts.

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hilton Hotels Corporation Common Stock

Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.

Read more on HLT

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK